Healionics’ Stargraft AV Dialysis Access Device Receives FDA Breakthrough Device Designation
Healionics, a medical technology company headquartered in Seattle, announced that its STARgraft arteriovenous (AV) graft for dialysis access has received Breakthrough Device designation from the FDA.
This designation recognizes the device’s significant advantages over existing alternatives. Based on Healionics’ synthetic biomaterial technology, STARgraft is designed to address the common issues of occlusion and infection that occur with existing AV vascular grafts.
As a graduate of the LSW Institute’s WIN Mentorship Program, Healionics is among the numerous Seattle-based biotech startups making innovative strides on a national scale.